Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 795-810 , December 2006

Alemtuzumab in T-cell lymphoproliferative disorders

  • Claire E. Dearden, BSc, MD, FRCP, FRCPath (Consultant Haematologist)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 20 8661 3655; Fax: +44 20 8642 9634.
    • ,
  • Estella Matutes, MD, PhD, FRCPath (Consultant Haematologist)

References 

  1. Leeumann A, Lifely MR, Schneider P, et al. Primary Structure of CD52. Journal of Biological Chemistry. 1995;270:6088–6099
  2. Gilleece MH, Dexter TM. Effects of CAMPATH-1H antibody on human haemopoietic progenitors in vitro. Blood. 1993;82:807–812
  3. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet. 1988;2:1394–1399
  4. Heit W, Bunjes D, Wiesneth M, et al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1H plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. British Journal of Haematology. 1986;64:479–486
  5. Dyer MJ, Hale G, Hayhoe FG, et al. Effects of Campath 1-H antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood. 1989;73:1431–1439
  6. Rowan W, Tite J, Topley P, et al. Cross-linking of the Campath 1-H antigen (CD52) mediates growth inhibition in human B- and T-lymphocytes cell lines and subsequent emergence of CD52-deficient cells. Immunology. 1998;95:427–436
  7. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vitro therapeutic responses to Campath-1H. Leukemia Research. 1998;22:1185–1191
  8. Jaffe ES, Harris N, Stein H, et al. Tumours of Haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours Lyon. France: IARC Press; 2001;
  9. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood. 1991;78:3269–3274
  10. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood. 2001;98(6):1721–1726
  11. Keating MJ, Cazin B, Coutre S, et al. Campath-1H Treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology. 2002;20:205–213
  12. Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genetics and Cytogenetics. 1991;55:1–9
  13. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proceedings of the National Academy of Sciences of the USA. 1994;91:12530–12534
  14. Madani A, Choukroun V, Soulier J, et al. Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. Blood. 1996;87:1923–1927
  15. Stoppa-Lyonnet D, Soulier J, Lauge A, et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 1998;91:3920–3926
  16. Dyer MJS, Hale G, Marcus RE, et al. Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leukemia and Lymphoma. 1990;2:179–190
  17. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. Journal of Clinical Oncology. 1994;12:2588–2593
  18. Lim SH, Davey G, Marcus R. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet. 1993;341:432–433
  19. Dearden C, Matutes E, Cazin B, et al. Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. Blood. 2003;102:[Abstract 2378]
  20. Hopfinger G, Busch R, Eichorst B, et al. T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) – a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL. Blood. 2005;106:[Abstract 2130]
  21. Lamy T, Loughran TP. Current concepts: large granular lymphocyte leukemia. Blood Reviews. 1999;13:230–240
  22. Krishnan B, Swansbury J, Cazin B, et al. Clinical outcome of Stem Cell Transplantation (SCT) in patients with T Cell Prolymphocytic Leukaemia(T-PLL) previously treated with Alemtuzumab: a multicentre experience. Blood. 2005;106:285-I;[Abstract 2005]
  23. Osuji N, Matutes E, Dearden C, et al. Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia. British Journal of Haematology. 2005;128(5):645–648
  24. Wong KF, Chan JC, Liu HS, et al. Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature. British Journal of Haematology. 2002;116:598–600
  25. Skacel M, Maciejewski J, Kandil D, et al. Recurrent genomic imbalances in T-cell Large Granular Lymphocytes (T-LGL) leukemia detected by array-based comparative genomic hybridization (CGH). Blood. 2003;102:[Abstract 4768]
  26. Bigouret V, Hoffmann T, Arlettaz L, et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood. 2003;101:3198–3204
  27. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood. 1994;84:2164–2170
  28. Osuji N, Del Giudice I, Matutes E, et al. Treatment of T-cell large granular lymphocytic leukaemia: The role for methotrexate and cyclosporine A in new, relapsed and refractory cases. Blood. 2003;102:[Abstract 1467]
  29. Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Alemtuzumab-1H). British Journal of Haematology. 2003;123:278–281
  30. Rosenblum MD, LaBelle JL, Chang CC, et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood. 2004;103:1969–1971
  31. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Medical Oncology. 2002;19(supplement):S27–S32
  32. Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Reviews in Clinical and Experimental Hematology. 2003;7:336–361
  33. Iwanaga R, Ohtani K, Hayashi T, et al. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene. 2001;20:2055–2067
  34. Kamada N, Sakurai M, Miyamoto K, et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. Cancer Research. 1992;52:1481–1493
  35. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. British Journal of Haematology. 2001;113:779–784
  36. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. The Hematology Journal. 2004;5:130–134
  37. Ishida T, Lida S, Akatsua Y, et al. CCR4: chemokine receptor as a novel molecular target for immunotherapy in adult T-cell leukemia/lymphoma (ATLL). Blood. 2003;102:[Abstract 3348]
  38. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Alemtuzumab-1H. Cancer Research. 2003;63:6453–6457
  39. Mone A, Puhalla S, Whitman S, et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α-refractory adult T-cell leukaemia. Blood. 2005;106(10):3380–3382
  40. Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukaemia (ATL) treated with combination of alemtuzumab and pentostatin. Leukemia Research. 2006;30(1):103–105
  41. Kim YH, Hoppe RT. Mycosis Fungoides and the Sezary syndrome. Seminars in Oncology. 1999;26:276–289
  42. Scarisbrick JJ, Woolford AJ, Russell-Jones R, et al. Allelotyping in mycosis fungoides and Sezary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. The Journal of Investigative Dermatology. 2001;117:663–670
  43. Kuzel TM, Roenigk HH, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. Journal of Clinical Oncology. 1995;13:257–263
  44. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology. 2001;19:2456–2471
  45. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98:993–1001
  46. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntingt). 2000;14:37–40
  47. Kuzel TM, Hurria A, Samuelson E, et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood. 1996;87:906–911
  48. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. Journal of Clinical Oncology. 1994;12:2051–2059
  49. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. Journal of the American Academy of Dermatology. 1998;39:63–73
  50. Obitz E, Kim YH, Iversen L, et al. HuMax-CD4, a fully human monoclonal antibody: early results of an ongoing phase II trial in cutaneous T cell lymphoma (CTCL). Blood. 2003;102:[Abstract 2383]
  51. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of Campath-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 1998;16:3257–3263
  52. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-Cd52 monoclonal antibody) in patients with advanced mycosis Fungoides/Sezary syndrome. Blood. 2003;101(11):4267–4272
  53. Foukaneli T, Marsh J, Pettengell R, et al. Sezary syndrome responds to treatment with Alemtuzumab-1H. Blood. 2001;98:[Abstract 556]
  54. Capalbo S, Delia M, Dargenio M, et al. Mycosis fungoides/Sezary syndrome: a report of three cases treated with Alemtuzumab-1H as salvage treatment. Medical Oncology. 2003;20:389–396
  55. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. European Journal of Haematology. 2003;71:250–256
  56. Lenihan DJ, Alencar AJ, Yang D, et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004;104(3):655–658
  57. Lundin J, Kennedy B, Dearden C, et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome. Blood. 2005;105(10):4148–4149
  58. Weder P, Anliker M, Itin P, et al. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. Dermatology. 2004;208:281–283
  59. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479
  60. Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. The American Journal of Pathology. 2004;164:1837–1848
  61. Dutcher JP. The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas. Leukemia Research. 2003;27:467–469
  62. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–2924
  63. Zinzani PL, Alinari L, Tani M, et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica. 2005;90(5):702–703
  64. Gallamini A, Zaja F, Gargantini L, et al. CHOP chemotherapy plus Alemtuzumab-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL). Annals of Oncology. 2005;16:[Abstract 321]
  65. Weidmann E, Hess G, Krause SW, et al. Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin; An effective first-line treatment in peripheral T-cell lymphomas. Annals of Oncology. 2005;16:[Abstract 232]
  66. Wulf GG, Hasenkamp J, Jung W, et al. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation. 2005;36(3):271–273
  67. Kahl C, Leithauser M, Wolff D, et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Annals of Hematology. 2002;81:646–650

PII: S1521-6926(06)00037-5

doi: 10.1016/j.beha.2006.05.005

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 795-810 , December 2006

Article Tools

* Image Usage & Resolution